Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613716 · ClinicalTrials.gov registry record · Phase 4
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
A Phase 4 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01613716 is a Phase 4 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 30 participants.
The verdict
NCT01613716, a Phase 4 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will examine the use of the dexamethasone implant (Ozurdex) in patients with macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention. After the surgery is performed (pars plana vitrectomy), an Ozurdex implant will be placed in the eye. Patients will be followed for 1 year.
Interventions
- DRUG Ozurdex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-07 |
| Est. Completion | 2017-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01613716
The ClinicalTrials.gov registry entry for NCT01613716 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ozurdex is the first listed.
NCT01613716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01613716 about?
NCT01613716 is a clinical study titled "Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)". This study will examine the use of the dexamethasone implant (Ozurdex) in patients with macular edema associated with an epiretinal or preretinal membrane requiring surgical intervention. After the surgery is performed (pars plana vitrectomy), an Ozurdex implant will be placed in the eye. Patients w...
What is the current status of trial NCT01613716?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2012-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01613716?
The interventions under investigation include: Ozurdex (DRUG).
Who is sponsoring clinical trial NCT01613716?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.